{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:47:08Z","timestamp":1761709628735,"version":"3.44.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.annder.2019.07.001","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T07:45:18Z","timestamp":1564127118000},"page":"659-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Place du rituximab dans le traitement de la pemphigo\u00efde des muqueuses"],"prefix":"10.1016","volume":"146","author":[{"given":"A.-S.","family":"Bertrand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Dereure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bessis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.07.001_bib0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2019.07.001_bib0070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annder.2011.01.014","article-title":"Recommandations des centres de r\u00e9f\u00e9rence des maladies bulleuses auto-immunes pour le diagnostic et la prise en charge de la pemphigo\u00efde cicatricielle","volume":"38","author":"Bedane","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.07.001_bib0075","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2019.07.001_bib0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2019.07.001_bib0085","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.annder.2019.07.001_bib0090","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2013.01.046","article-title":"Treatment of mucous membrane pemphigoid with rituximab","volume":"69","author":"Heelan","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.07.001_bib0095","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/14712598.2015.1046833","article-title":"Rituximab preserves vision in ocular mucous ou membrane pemphigoid","volume":"15","author":"R\u00fcbsam","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.annder.2019.07.001_bib0100","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2016.01.020","article-title":"Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP)","volume":"74","author":"Maley","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.07.001_bib0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2012.10.018","article-title":"Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature","volume":"68","author":"Shetty","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.07.001_bib0110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.oooo.2015.01.024","article-title":"World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid","volume":"120","author":"Taylor","year":"2015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.annder.2019.07.001_bib0115","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.07.001_bib0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","article-title":"Suppression of normal immune responses after treatment with rituximab","volume":"28","author":"Kado","year":"2016","journal-title":"Curr Opin Rheumatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819302509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819302509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:07:54Z","timestamp":1758971274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819302509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0151963819302509"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.07.001","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Place du rituximab dans le traitement de la pemphigo\u00efde des muqueuses","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}